Form 4: Tarsus COO Sells Shares Under 10b5-1 Plan

Tarsus Pharmaceuticals' Chief Operating Officer, Neervannan Seshadri, sold 8,366 shares of common stock for $76.67 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Neervannan Seshadri, Chief Operating Officer of Tarsus Pharmaceuticals, Inc., reported a sale of company common stock.
• A total of 8,366 shares were disposed of at a price of $76.67 per share.
• The transaction occurred on March 4, 2026.
• The sale was executed automatically under a Rule 10b5-1 trading plan established by the Reporting Person on November 13, 2025.
• Following the transaction, Seshadri directly owns 70,817 shares and indirectly owns 475 shares through his daughter, for which he disclaims beneficial ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, pre-scheduled transaction under a 10b5-1 plan, which typically does not signal a change in management's outlook on the company.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and non-discretionary transaction rather than an immediate reaction to new information.

Negatives

• An insider sale, even if pre-planned, reduces the officer's direct equity stake in the company.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the pharmaceutical industry as executives manage their personal portfolios and liquidity needs. These pre-scheduled sales are generally viewed as less indicative of management's immediate sentiment about the company's prospects compared to unscheduled, discretionary sales.

Related Party Transactions

• The reporting person's daughter holds 475 shares indirectly, though the reporting person disclaims beneficial ownership of these securities.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but mitigated by the pre-planned nature of the sale.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

The insider sale is a routine, pre-scheduled event under a 10b5-1 plan and does not provide new material information to warrant a change in investment thesis. It's a standard liquidity event for an executive, not an indicator of fundamental company performance or future prospects.

Keywords

Tarsus Pharmaceuticals, TARS, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Neervannan Seshadri, Chief Operating Officer, Equity Transaction